Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival

Annals of Oncology

Volumn 10, Issue 4, 1999, Pages 433-440

  Sarris, A H ^a   Kliche, K O ^a   Pethambaram, P ^b   Preti, A ^a   Tucker, S ^a   Jackow, C ^a   Messina, O ^a   Pugh, W ^a   Hagemeister, F B ^a   McLaughlin, P ^a   Rodriguez, M A ^a   Romaguera, J ^a   Fritsche, H ^a   Witzig, T ^b   Duvic, M ^a   Andreeff, M ^a   Cabanillas, F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Failure free survival; Hodgkin's disease; IL 10

Indexed keywords

BETA 2 MICROGLOBULIN; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; INTERLEUKIN 10; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REED STERNBERG CELL;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HODGKIN DISEASE; HUMANS; INTERLEUKIN-10; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032964570     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008301602785     Document Type: Article

References (63)

1. Longo DL, Young RC, Wesley M et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 4:1295-306, 1986
2. De Vita VTJ, Hellman S, Jaffe ES. Hodgkin's disease. In De Vita VTJ, Hellman S, Rosenberg SA (eds): Cancer, Principles & Practice of Oncology, Fourth Edition. Philadelphia: JB Lippincott 1993; 1819-58.
3. Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478-84.
4. Straus DJ, Gaynor JJ, Myers J et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 1990; 8: 1173-86.
5. Proctor SJ, Taylor P, Mackie MJ et al. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. Leuk Lymph 1992; 7: 17-20.
6. Gisselbrecht C, Ferme C. Prognostic factors in advanced Hodgkin's disease: Problems and pitfalls. Towards an international prognostic index. Leuk Lymph 1995; 1: 23-4.
7. Ferme C, Lepage E, Bastion Y et al. Advanced Hodgkin's disease: Validation of the MSKCC prognostic model. How to identify a high-risk group qualifying for intensive initial treatment? The GELA study. Ann Oncol 1996; 7 (Suppl 3): 112.
8. Sarris AH, Straus D, Preti A et al. A prognostic model for advanced Hodgkin's disease at M.D. Anderson validated with an independent set of patients treated at Memorial Sloan-Kettering. Blood 1996; 88 (Suppl 1): 893a.
9. Sarris A, Daliani D, Mesina O et al. A Prognostic model for failure-free survival (FFS) of adults with clinical Ann Arbor stage (AAS) I-II Hodgkin's disease (HD) after combined modality therapy. J Clin Oncol 1997; 16: 7a.
10. Sarris A, Preti A, Mesina O et al. A predictive model for failure-free survival (FFS) of adults with Hodgkin's disease treated with ABVD or equivalent regimens. Blood 1997; 90 (Suppl 1): 388a.
11. Hasenclever D, Diehl V. A progostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339: 1506-14.
12. Anagnostopoulos I, Herbst H, Niedobitek G et al. Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1-positive anaplastic large-cell lymphoma by combined Southern blot and in situ hybridization. Blood 1989; 74: 810-6.
13. Weinreb M, Day PJ, Murray PG et al. Epstein-Barr virus (EBV) and Hodgkin's disease in children: Incidence of EBV latent membrane protein in malignant cells. J Pathol 1992; 168: 365-9.
14. Ambinder RF, Browning PJ, Lorenzana I et al. Epstein-Barr virus and childhood Hodgkin's disease in Honduras and the United States. Blood 1993; 81: 462-7.
15. Chang KL, Albujar PF, Chen YY et al. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of Hodgkin's disease occurring in Peru. Blood 1993; 81: 496-501.
16. Quintanilla-Martinez L, Gamboa-Domnquez A, Gamez-Ledesma I et al. Association of Epstein-Barr virus latent membrane protein and Hodgkin's disease in Mexico. Mod Pathol 1995; 8: 675-9.
17. Ohshima K, Suzumiya J, Akamatu M et al. Human and viral interleukin-10 in Hodgkin's disease, and its influence on CD4+ and CDS+ T lymphocytes. Int J Cancer 1995; 62: 5-10.
18. Weinreb M, Day PJR, Niggli F et al. The consistent association between Epstein-Barr virus and Hodgkin's disease in children in Kenya. Blood 1996; 87: 3828-36.
19. Huh J, Park C, Juhng S et al. A pathologic study of Hodgkin's disease in Korea and its association with Epstein-Barr virus infection. Cancer 1996; 77: 949-55.
20. Herbst H, Foss H-D, Samol J et al. Frequent expression of Interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood 1996; 87: 2918-29.
21. Sarris AH, Medeiros LJ, Herling M et al. The expression of the EBV-coded latent membrane protein-1 (LMP-1) In Reed-Sternberg cells of Hodgkin's disease (HD) is associated with higher serum IL-10 levels and inferior failure-free survival (FFS). Blood 1998; 92 (Suppl 1): 353a.
22. Armstrong AA, Alexander FE, Paes RP et al. Association of Epstein-Barr virus with pediatric Hodgkin's disease. Am J Pathol 1993; 142: 1683-8.
23. Fahraeus R, Rymo L, Rhim JS et al. Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature 1990; 345: 447-9.
24. Dawson CW, Rickinson AB, Young LS. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 1990; 344: 777-80.
25. Herbst H, Dallenbach F, Hummel M et al. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci USA 1991; 88: 4766-70.
26. Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA 1993; 90: 9150-4.
27. Rowe M, Peng-Pilon M, Huen DS et al. Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: A B cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers. J Virol 1994; 68: 5602-12.
28. Henderson S, Rowe M, Gregory C et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991; 65: 1107-15.
29. Deisseroth AB, De Vita VTJ. The cell cycle: Probing new molecular determinants of resistance and sensitivity to cytotoxic agents. The Cancer Journal, Scientific American 1995; 1: 15-21.
30. Rowe M, Rowe DT, Gregory CD et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. Embo J 1987; 6: 2743-51.
31. Thorley-Lawson DA, Israelsohn ES. Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein. Proc Natl Acad Sci USA 1987; 84: 5384-8.
32. Murray RJ, Wang D, Young LS et al. Epstein-Barr virus-specific cytotoxic T cell recognition of transfectants expressing the virus-coded latent membrane protein LMP. J Virol 1988; 62: 3747-55.
33. Hamilton-Dutoit SJ, Rea D, Raphael M et al. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. Am J Pathol 1993; 143: 1072-85.
34. Chen HF, Kevan-Jah S, Suentzenich KO et al. Expression of the Epstein-Barr virus latent membrane protein (LMP) in insect cells and detection of antibodies in human sera against this protein. Virology 1992; 190: 106-15.
35. Taga K, Cherney B, Tosato G. IL-10 inhibits apoptotic cell death in human T cells starved of IL-2. Int Immunol 1993; 5: 1599-608.
36. Taga K, Chretien J, Cherney B et al. Interleukin-10 inhibits apoptotic cell death in infectious mononucleosis T cells. J Clin Invest 1994; 94: 251-60.
37. Brunetti M, Martelli N, Colasante A et al. Spontaneous and glucocorticoid induced apoptosis in human mature T lymphocytes. Blood 1995; 86: 4199.
38. Weber-Nordt RM, Henschler R, Schott E et al. Interleukin-10 increases bcl-2 expression and survival in primary human CD34+ hematopietic progenitor cells. Blood 1996; 88: 2549-58.
39. Voorzanger-Rousselot N, Favrot M-C, Blay JY. Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells. Blood 1998; 92: 3381-7.
40. Barth S, Klimka A, Matthey B et al. Cytokine fusiontoxins show specific potency against Hodgkin lymphoma cells in vitro. Leuk Lymph 1998; 29 (Suppl 1): 107.
41. Küpers R, Hansmann ML, Rajewsky K. Clonality and germinal centre B-cell derivation of Hodgkin-Reed-Sternberg cells in Hodgkin's disease. Ann Oncol 1998; 9 (Suppl 5): S17-20.
42. Wang L, Goillot E, Tepper RI. IL-10 inhibits alloreactive cytotoxic T lymphocyte generation in vivo. Cell Immunol 1994; 159: 152-69.
43. Suzuki T, Tahara H, Narula S et al. Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors. J Exp Med 1995; 182: 477-86.
44. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res 1966; 26: 1063-83.
45. Harris NL, Jaffe ES, Stein H et al. A Revised European-American Classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
46. Carbone PP, Kaplan HS, Musshoff K et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860-1.
47. Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of eight-year results. Ann Intern Med 1986; 104: 739-46.
48. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 257-481.
49. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-70.
50. Cox DR. Regression models and life tables (with Discussion). J R Stat Soc B 1972; 34: 187-220.
51. Mori N, Gill PS, Mougdil T et al. Interleukin-10 gene expression in adult T-cell leukemia. Blood 1996; 88: 1035-45.
52. Loeffler M, Brosteanu O, Hasenclever D et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. J Clin Oncol 1998; 16: 818-29.
53. Hasenclever D, Diehl V. A numerical index to predict tumor control in advanced Hodgkin's disease. Blood 1996; 88 (Suppl 1): 673a.
54. Koury MJ. Programmed cell death (apoptosis) in hematopoiesis. Exp Hematol 1992; 20: 391.
55. Hell K, Lorenzen J, Fischer R et al. Hodgkin cells accumulate mRNA for bcl-2. Lab Invest 1995; 73: 492-6.
56. Lorenzen J, Hansmann ML, Pezzella F et al. Expression of the bcl-2 oncogene product and chromosomal translocation t(14;18) in Hodgkin's disease. Hum Pathol 1992; 23: 1205-9.
57. Dimopoulos MA, Cabanillas F, Lee JJ et al. Prognostic role of serum beta 2-microglobulin in Hodgkin's disease. J Clin Oncol 1993; 11: 1108-11.
58. Longo DL, Glatstein E, Duffey PL et al. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. Blood 1997; 15: 3338-46.
59. Huhn RD, Radwanski E, O'Connell SM et al. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood 1996; 87: 699-705.
60. Huhn RD, Pennline K, Radwanski E et al. Recombinant human Interleukin-10 (RHIL-10) - safety, pharmakodynamics and immunohematologic effects of repeated daily subcutaneous (s.c.) doses in healthy volunteers. Blood 1997; 90 (Suppl 1): 280a.
61. Geissler K, Öhler L, Födinger M et al. Interleukin-10 inhibits erytropoietin-independent growth of erythroid bursts in patients with polycythemia vera. Blood 1998; 92: 1967-72.
62. Colonna P, Jais JP, Desablens B et al. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: Ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients. J Clin Oncol 1996; 14: 1928-35.
63. Bonfante V, Viviani S, Notti S et al. Interleukin-10 (IL-10) basal serum levels correlate with relapse in Hodgkin disease (HD). Leuk Lymph 1998; 29 (Suppl 1): 31.